ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 201

Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims

Jasvinder A. Singh1 and Shaohua Yu2, 1Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Allopurinol, coronary artery disease, Elderly, myocardial involvement and pharmacotherapy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess whether allopurinol use reduces the risk of myocardial infarction (MI) in the elderly.

Methods: We used the 2006-2012 5% random sample of Medicare beneficiaries to study the association of new allopurinol initiation and the risk of incident MI, in a cohort study. Multivariable-adjusted Cox regression models adjusted for age, gender, race and Charlson index, in addition to various cardio-protective medications (beta-blockers, ACE inhibitors, diuretics, statins). We calculated hazards ratio (HR) with 95% confidence intervals (CI). Sensitivity analyses adjusted for coronary artery disease (CAD) risk factors including hypertension, hyperlipidemia, diabetes, and smoking.

Results: 1,544 of the 29,298 episodes of incident allopurinol use were associated with incident MI (5.3% episodes). Allopurinol use was associated with reduced hazards of MI, with HR of 0.85 (95% CI, 0.77 to 0.95). Compared to no allopurinol use, longer allopurinol use durations were associated with lower HR of MI: 1-180 days, 0.98 (95% CI, 0.84 to 1.14); 181 days to 2 years, 0.83 (95% CI, 0.72 to 0.95); and >2 years, 0.70 (95% CI, 0.56 to 0.88). Other factors associated with higher hazard of MI were: age 75-<85 and ≥85, male gender, higher Charlson index score and the use of ACE-inhibitor. Adjustment for CAD risk factors confirmed these findings.

Conclusion: Incident allopurinol use was associated with a reduction in the risk of incident MI. Longer allopurinol use durations reduced the risk of incident MI incrementally. Future studies need to assess underlying mechanisms of this association and to assess risk-benefit ratio of allopurinol use for MI prevention.


Disclosure: J. A. Singh, TAP, Savient, 2,Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology, 5; S. Yu, None.

To cite this abstract in AMA style:

Singh JA, Yu S. Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/allopurinol-reduces-the-risk-of-myocardial-infarction-mi-in-the-elderly-a-study-of-medicare-claims/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/allopurinol-reduces-the-risk-of-myocardial-infarction-mi-in-the-elderly-a-study-of-medicare-claims/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology